Scott Zamvil

Summary

Publications

  1. pmc B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity
    Martin S Weber
    Department of Neurology and Program in Immunology, University of California, San Francisco, CA 94143 0114, USA
    Ann Neurol 68:369-83. 2010
  2. pmc Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin
    Shannon E Dunn
    Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA
    J Exp Med 203:401-12. 2006
  3. pmc Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica
    Patricia A Nelson
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e15050. 2010
  4. pmc Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter
    Michel Varrin-Doyer
    Departments of Neurology, University of California at San Francisco, USA
    Ann Neurol 72:53-64. 2012
  5. pmc Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease
    Martin S Weber
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    PLoS ONE 5:e16009. 2010
  6. pmc Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity
    Ulf Schulze-Topphoff
    Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e33797. 2012
  7. ncbi request reprint Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity
    Martin S Weber
    Department of Neurology, University of California, 675 Nelson Rising Lane NS 215A, San Francisco, CA 94158, USA
    J Neuroinflammation 11:29. 2014
  8. pmc The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis
    Petra D Cravens
    Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9036, USA
    J Neuroinflammation 10:67. 2013
  9. pmc Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet
    Petra D Cravens
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, USA
    J Neuroinflammation 8:73. 2011
  10. ncbi request reprint Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis
    Scott S Zamvil
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA
    Neuron 38:685-8. 2003

Collaborators

Detail Information

Publications38

  1. pmc B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity
    Martin S Weber
    Department of Neurology and Program in Immunology, University of California, San Francisco, CA 94143 0114, USA
    Ann Neurol 68:369-83. 2010
    ..We investigated mechanisms of anti-CD20-mediated immune modulation using 2 paradigms of experimental autoimmune encephalomyelitis (EAE)...
  2. pmc Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin
    Shannon E Dunn
    Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA
    J Exp Med 203:401-12. 2006
    ..Thus, by connecting isoprenoid availability to regulation of Th1/Th2 fate, we have elucidated a mechanism by which AT may suppress Th1-mediated central nervous system autoimmune disease...
  3. pmc Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica
    Patricia A Nelson
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e15050. 2010
    ..Our identification of the AQP4 T cell determinants and characterization of its immunodominant determinant should permit investigators to evaluate the role of AQP4-specific T cells in vivo and to develop AQP4-targeted murine NMO models...
  4. pmc Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter
    Michel Varrin-Doyer
    Departments of Neurology, University of California at San Francisco, USA
    Ann Neurol 72:53-64. 2012
    ..Our goal was to identify and characterize AQP4-specific T cells in NMO patients and healthy controls (HC)...
  5. pmc Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease
    Martin S Weber
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    PLoS ONE 5:e16009. 2010
    ..Besides its therapeutic implication, this finding suggests that encounter of the immune system with microbial products may not only be part of CNS autoimmune disease pathogenesis but also of its regulation...
  6. pmc Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity
    Ulf Schulze-Topphoff
    Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e33797. 2012
    ..Thus, laquinimod modulates adaptive T cell immune responses via its effects on cells of the innate immune system, and may not influence T cells directly...
  7. ncbi request reprint Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity
    Martin S Weber
    Department of Neurology, University of California, 675 Nelson Rising Lane NS 215A, San Francisco, CA 94158, USA
    J Neuroinflammation 11:29. 2014
    ..This cytostatic effect may be a relevant mechanism of action when considering use of statins in MS and other inflammatory conditions. ..
  8. pmc The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis
    Petra D Cravens
    Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9036, USA
    J Neuroinflammation 10:67. 2013
    ..In contrast, IL-17 transcripts could not be detected in adult or neonate CNS in this EAE model, and neither adult nor neonate donor CD4+ T cells expressed IL-17 at the time of adoptive transfer...
  9. pmc Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet
    Petra D Cravens
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, USA
    J Neuroinflammation 8:73. 2011
    ..Our data further suggest that GM-CSF expression by CD4+ T cells regulated by IL-23 contributes to their encephalitogenicity in our EAE model...
  10. ncbi request reprint Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis
    Scott S Zamvil
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA
    Neuron 38:685-8. 2003
    ..While remyelination can occur during the early inflammatory phase when damage may be reversible, it is impaired in the later stages, which involve axonal death. These observations have important therapeutic implications...
  11. ncbi request reprint Transcriptional analysis of targets in multiple sclerosis
    Lawrence Steinman
    Beckman Center for Molecular Medicine B002, Stanford University, Stanford, California 94305, USA
    Nat Rev Immunol 3:483-92. 2003
    ..This review focuses on multiple sclerosis and on the approaches that are being used to identify new targets that might be manipulated to control this disease...
  12. ncbi request reprint Statins as potential therapeutic agents in neuroinflammatory disorders
    Olaf Stuve
    Department of Neurology, University of California, San Francisco, California 94143, USA
    Curr Opin Neurol 16:393-401. 2003
    ..In this article we will review those findings that indicate that statins may be beneficial in the treatment of multiple sclerosis, neurodegenerative disease, and ischemic stroke...
  13. ncbi request reprint Drug Insight: using statins to treat neuroinflammatory disease
    Martin S Weber
    University of California San Francisco UCSF, CA 94143, USA
    Nat Clin Pract Neurol 1:106-12. 2005
    ....
  14. doi request reprint Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab
    Maria del Pilar Martin
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Neurology Section, Veterans Affairs North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216, USA
    Arch Neurol 65:1596-603. 2008
    ..We hypothesized that natalizumab reduces the number of antigen presenting cells in CPVS...
  15. ncbi request reprint Type II monocytes modulate T cell-mediated central nervous system autoimmune disease
    Martin S Weber
    Department of Neurology and Program in Immunology, University of California, San Francisco, 513 Parnassus Avenue, S 268, San Francisco, California 94143 0435, USA
    Nat Med 13:935-43. 2007
    ..This demonstration of adoptive immunotherapy by type II monocytes identifies a central role for these cells in T cell immune modulation of autoimmunity...
  16. ncbi request reprint Statins as potential therapeutic agents in multiple sclerosis
    Olaf Stuve
    Department of Neurology, University of California San Francisco, 521 Parnassus Avenue, C 440, San Francisco, CA 94143 0114, USA
    Curr Neurol Neurosci Rep 4:237-44. 2004
    ..Whether statins will be of clinical benefit for patients with multiple sclerosis and other neurodegenerative diseases of the central nervous system will only be known after they are evaluated in prospective randomized clinical trials...
  17. ncbi request reprint Statins and their potential targets in multiple sclerosis therapy
    Olaf Stuve
    Department of Neurology, University of California, San Francisco, 521 Parnassus Avenue, C 440, San Francisco, CA 94143 0114, USA
    Expert Opin Ther Targets 7:613-22. 2003
    ..This article will outline experimental evidence that suggests potential clinical benefits of statins for MS patients...
  18. doi request reprint Depletion of B lymphocytes from cerebral perivascular spaces by rituximab
    Maria del Pilar Martin
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Arch Neurol 66:1016-20. 2009
    ..We and other investigators previously demonstrated that rituximab therapy depletes B lymphocytes from peripheral blood and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis...
  19. ncbi request reprint Statins in the treatment of central nervous system autoimmune disease
    Martin S Weber
    Department of Neurology and Program in Immunology, University of California, San Francisco, USA
    J Neuroimmunol 178:140-8. 2006
    ..Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials...
  20. ncbi request reprint Statins--treatment option for central nervous system autoimmune disease?
    Martin S Weber
    Department of Neurology and Program in Immunology, University of California, San Francisco, California 94143, USA
    Neurotherapeutics 4:693-700. 2007
    ..Based primarily on these encouraging results, statins are now being tested in clinical trials as a monotherapy for multiple sclerosis, as well as in combination with approved disease-modifying therapies...
  21. ncbi request reprint Mechanism of action of glatiramer acetate in treatment of multiple sclerosis
    Martin S Weber
    Department of Neurology and Program in Immunology, University of California, San Francisco, CA 94143, USA
    Neurotherapeutics 4:647-53. 2007
    ..These new findings represent a plausible explanation for GA-mediated T-cell immune modulation and may provide useful insight for the development of new and more effective treatment options for multiple sclerosis...
  22. pmc Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity
    Olaf Stuve
    Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, California, USA
    J Clin Invest 116:1037-44. 2006
    ..Our results demonstrate that agents with different mechanisms of immune modulation can combine in a synergistic manner for the treatment of CNS autoimmunity and provide rationale for testing the combination of atorvastatin and GA in MS...
  23. ncbi request reprint Simvastatin regulates oligodendroglial process dynamics and survival
    Veronique E Miron
    Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
    Glia 55:130-43. 2007
    ..Our findings indicate the importance of considering the short- and long-term effects of systemic immunomodulatory therapies on neural cells affected by the MS disease process. (c) 2006 Wiley-Liss, Inc...
  24. ncbi request reprint Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice
    Fiona Costello
    Departments of Medicine, The University of Ottawa, Ottawa, Ontario, Canada
    Curr Opin Neurol 20:281-5. 2007
    ..To outline the scientific rationale for combination therapy in multiple sclerosis and to discuss the evidence for combination treatment strategies from animal models and clinical trials of multiple sclerosis...
  25. ncbi request reprint Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS
    Scott S Zamvil
    Neurology 59:970-1. 2002
  26. ncbi request reprint The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
    Sawsan Youssef
    Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University, Stanford, California 94305, USA
    Nature 420:78-84. 2002
    ..Thus, atorvastatin has pleiotropic immunomodulatory effects involving both APC and T-cell compartments. Statins may be beneficial for multiple sclerosis and other Th1-mediated autoimmune diseases...
  27. ncbi request reprint Efficient technique for immortalization of murine microglial cells relevant for studies in murine models of multiple sclerosis
    Julie K Olson
    Department of Microbiology Immunology and Interdepartmental Immunobiology Program, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA
    J Neurosci Methods 128:33-43. 2003
    ..This technique should allow for the efficient cultivation of large numbers of microglial cells from a variety of disease-relevant mouse strains, including knock-out and transgenic mice...
  28. ncbi request reprint Are statins a treatment option for multiple sclerosis?
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Lancet Neurol 3:369-71. 2004
    ..Thus, identifying new effective therapeutic options with few side-effects is highly desirable...
  29. ncbi request reprint Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
    Timothy K Vartanian
    Multiple Sclerosis Division, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Neurology 63:S42-9. 2004
    ..Long-term prospective studies are needed to further define the clinical effects of NAbs on patients receiving disease-modifying therapies for MS...
  30. ncbi request reprint Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis
    Lawrence Steinman
    Department of Neurology and Neurological Sciences, Chair Interdepartmental Program in Immunology, Stanford University, Stanford, CA 94305, USA
    Trends Immunol 26:565-71. 2005
    ..However, EAE has failed to predict the outcome of certain approaches. The reasons underlying such failures are discussed here...
  31. ncbi request reprint Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles
    Oliver Neuhaus
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    CNS Drugs 19:833-41. 2005
    ....
  32. pmc Statin therapy and autoimmune disease: from protein prenylation to immunomodulation
    John Greenwood
    Department of Cell Biology, Institute of Ophthalmology, University College London, London EC1V 9EL, UK
    Nat Rev Immunol 6:358-70. 2006
    ..In this Review, the effect of statin therapy on immune function, and how this relates to the pathogenesis of autoimmune disease, is reviewed alongside current opinion of what the key biological targets of statins are...
  33. ncbi request reprint How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis
    Lawrence Steinman
    Department of Neurology and Neurological Sciences, Stanford University, CA 94305, USA
    Ann Neurol 60:12-21. 2006
    ..There are pitfalls in overreliance on the EAE model, or on any animal model for any human disease. Nevertheless, over the past 73 years, the EAE model has proved itself remarkably useful for aiding research on MS...
  34. doi request reprint Bench to bedside: tempering antigen-presenting cells in multiple sclerosis
    Thomas Prod'homme
    Nat Med 14:614-5. 2008
  35. ncbi request reprint The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists
    Edward J Fox
    University of Texas Medical Branch, MS Clinic of Central Texas, Round Rock, Texas 78681, USA
    Neurologist 13:355-62. 2007
    ..Therefore, it is important to understand the causes of immunogenicity, methods for assessing antibody status, and the clinical impact of NAbs, particularly in patients who appear to be nonresponsive to treatment...
  36. ncbi request reprint Pharmacological treatment of early multiple sclerosis
    Olaf Stuve
    Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas 75216, USA
    Drugs 68:73-83. 2008
    ....
  37. ncbi request reprint T effectors outfox T regulators in autoimmunity
    Thomas Prod'homme
    Nat Med 13:411-3. 2007
  38. ncbi request reprint Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate
    Jeanne M Soos
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 169:2231-5. 2002
    ..This combination was associated with TGF-beta secretion and enhanced IL-10 production. Thus, IFN-tau is a potential candidate for use as a single agent or in combination therapy for multiple sclerosis...

Research Grants15

  1. Regulatory monocytes in CNS autoimmune disease
    Scott S Zamvil; Fiscal Year: 2010
    ..These studies should provide insight leading to the development of reagents that may promote type II APC differentiation and T cell immune modulation more effectively than GA. ..
  2. B cells in CNS autoimmunity
    Scott S Zamvil; Fiscal Year: 2010
    ..Our research program will also evaluate how anti-CD20 B cell depletion, a therapeutic approach being investigated in MS clinical trials, may influence immune regulation. Page 5 ..
  3. Immunomodulation of inflammatory disease by atorvastatin
    Scott Zamvil; Fiscal Year: 2009
    ..These studies have direct and immediate applicability to the use of statins in treatment of autoimmune disease. ..
  4. MHC class II regulation and antigen processing in EAE
    Scott Zamvil; Fiscal Year: 2007
    ..These studies will provide valuable information regarding CNS class II regulation, which may provide insight for development of therapeutic means to modulate class II expression and T cell activation in MS. ..
  5. Immunomodulation of inflammatory disease by atorvastatin
    Scott Zamvil; Fiscal Year: 2007
    ..These studies have direct and immediate applicability to the use of statins in treatment of autoimmune disease. ..
  6. Immunomodulation of inflammatory disease by atorvastatin
    Scott Zamvil; Fiscal Year: 2006
    ..These studies have direct and immediate applicability to the use of statins in treatment of autoimmune disease. ..
  7. Immunomodulation of inflammatory disease by atorvastatin
    Scott Zamvil; Fiscal Year: 2005
    ..These studies have direct and immediate applicability to the use of statins in treatment of autoimmune disease. ..
  8. MHC class II regulation and antigen processing in EAE
    Scott Zamvil; Fiscal Year: 2005
    ..These studies will provide valuable information regarding CNS class II regulation, which may provide insight for development of therapeutic means to modulate class II expression and T cell activation in MS. ..
  9. MHC class II regulation and antigen processing in EAE
    Scott Zamvil; Fiscal Year: 2004
    ..These studies will provide valuable information regarding CNS class II regulation, which may provide insight for development of therapeutic means to modulate class II expression and T cell activation in MS. ..
  10. MHC class II regulation and antigen processing in EAE
    Scott Zamvil; Fiscal Year: 2006
    ..These studies will provide valuable information regarding CNS class II regulation, which may provide insight for development of therapeutic means to modulate class II expression and T cell activation in MS. ..
  11. B cells in CNS autoimmunity
    Scott Zamvil; Fiscal Year: 2009
    ..Our research program will also evaluate how anti-CD20 B cell depletion, a therapeutic approach being investigated in MS clinical trials, may influence immune regulation. Page 5 ..
  12. Regulatory monocytes in CNS autoimmune disease
    Scott Zamvil; Fiscal Year: 2009
    ..These studies should provide insight leading to the development of reagents that may promote type II APC differentiation and T cell immune modulation more effectively than GA. ..
  13. MHC CLASS II TRANSACTIVATOR (CIITA) IN CNS AUTOIMMUNITY
    Scott Zamvil; Fiscal Year: 2004
    ....